NF 1819

Product Description

NF 1819 is a potent and selective irreversible MAGL inhibitor (IC₅₀ values are 0.25 and 7.4 nM at rMAGL and hMAGL, respectively). Exhibits 389-fold selectivity over hFAAH and exhibits minimal binding at CB receptors (IC₅₀ > 10 μM). Alleviates symptoms in a MS in vivo model. Exhibits analgesic effects in an acute inflammatory pain model in vivo. Ameliorates neuropathic hypersensitivity induced by oxaliplatin (Cat. No. 2623). Displays high membrane permeability and brain penetrant.

Solubility

Preparing Stock Solutions for NF 1819

The following data is based on the product molecular weight 463.46

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.16 mL	10.79 mL	21.58 mL
5 mM	0.43 mL	2.16 mL	4.32 mL
10 mM	0.22 mL	1.08 mL	2.16 mL
50 mM	0.04 mL	0.22 mL	0.43 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Brindisi Development and pharmacological characterization of selective blockers of 2-arachidonoyl glycerol degradation with efficacy in rodent models of multiple sclerosis and pain. J.Med.Chem. 20106 PMID: 26888301